Digital Microfluidic Point of Care Platform for Molecular Detection of STI Pathogens Including Drug-Resistant Gonorrhea

Untreated sexually transmitted infections (STIs) are associated with numerous comorbidities, including decreased fertility, an increased risk of cervical cancer, a higher risk of HIV/AIDS, and neonatal complications. Most STIs are highly treatable, and rapid, point-of-care pathogen identification coupled with antibiotic resistance testing would significantly improve initial health outcomes, reduce follow-up appointments, and support personalized healthcare.

In this poster presented at the Association for Molecular Pathology (AMP) 2023 Annual Meeting & Expo in Salt Lake City, Utah, we introduced a digital microfluidic (DMF) molecular diagnostic platform that identifies Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), ciprofloxacin-resistant NG, and Trichomonas vaginalis (TV) from urine and vaginal swab samples within 20 minutes.

Digital Microfluidic Point of Care Platform for Molecular Detection of STI Pathogens Including Drug-Resistant Gonorrhea